Epithalon
Epitalon (L-alanyl-L-alpha-glutamyl-L-alpha-aspartyl-glycine; AEDG peptide)
Access and compounding status raise extra safety and legal questions.
A synthetic short peptide that activates an enzyme which helps maintain the protective caps on your chromosomes (the structures that carry your DNA), and may also support natural melatonin production for sleep. Most evidence comes from laboratory research and small clinical programs; large, rigorous human trials are lacking.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Adverse event reporting for epithalon is sparse. The retinitis pigmentosa clinical program (162 patients) reported no side effects, and a 15-year follow-up study with epithalamin showed no adverse events (PMID 40141333). However, the 2025 review emphasizes that critical short- and long-term toxicity, genotoxicity, carcinogenic potential, and drug interaction studies remain missing. The FDA flags immunogenicity, aggregation, and peptide-impurity risks for compounded epithalon products. The side effects listed above are primarily sourced from vendor safety pages and community reports, not from rigorous clinical trial adverse event monitoring.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-25]